(RVTY)

0.00

0.00 (0.00%)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

(RVTY)

0.00

0.00 (0.00%)

10.03.2026

Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

04.03.2026

Why Is Revvity (RVTY) Down 5.1% Since Last Earnings Report?

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?

04.03.2026

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY gains from strong diagnostics demand and fast-growing Signals software, but China policy pressure and weak research spending temper near-term growth.

03.03.2026

Revvity, Inc. (RVTY) Presents at TD Cowen 46th Annual Health Care Conference Transcript

02.03.2026

Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

17.02.2026

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Raymond James 47th Annual Institutional Investors Conference Monday, March 2, 2026 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 46th Annual Health Care Conference Tuesday, March 3, 2026 2:30 p.m. ET - Prahlad Singh, president and chief executive officer Barclays 28th Annual Global Healthcare Conference Tuesday, March 10,.

05.02.2026

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation,.

Videolar

No Data

There is no data to display

Press-relizlar

05.02.2026

Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation,.

02.02.2026

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for t.

26.01.2026

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from disco.

12.01.2026

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Inves.